ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10376755" target="_blank" >RIV/00216208:11110/18:10376755 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/18:10376755
Result on the web
<a href="https://doi.org/10.1177/1352458517751049" target="_blank" >https://doi.org/10.1177/1352458517751049</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1177/1352458517751049" target="_blank" >10.1177/1352458517751049</a>
Alternative languages
Result language
angličtina
Original language name
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Original language description
Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling current data to aid professionals in treatment decisions. Objectives: To develop an evidence-based clinical practice guideline for the pharmacological treatment of people with MS. Methods: This guideline has been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology and following the updated EAN recommendations. Clinical questions were formulated in Patients-Intervention-Comparator-Outcome (PICO) format and outcomes were prioritized. The quality of evidence was rated into four categories according to the risk of bias. The recommendations with assigned strength (strong and weak) were formulated based on the quality of evidence and the risk-benefit balance. Consensus between the panelists was reached by use of the modified nominal group technique. Results: A total of 10 questions were agreed, encompassing treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and treatment strategies in MS and pregnancy. The guideline takes into account all disease-modifying drugs approved by the European Medicine Agency (EMA) at the time of publication. A total of 21 recommendations were agreed by the guideline working group after three rounds of consensus. Conclusion: The present guideline will enable homogeneity of treatment decisions across Europe.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30103 - Neurosciences (including psychophysiology)
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Multiple Sclerosis Journal
ISSN
1352-4585
e-ISSN
—
Volume of the periodical
24
Issue of the periodical within the volume
2
Country of publishing house
GB - UNITED KINGDOM
Number of pages
25
Pages from-to
96-120
UT code for WoS article
000429033400085
EID of the result in the Scopus database
2-s2.0-85041492438